OmniAb (NASDAQ:OABI – Get Free Report) is expected to post its quarterly earnings results after the market closes on Tuesday, March 18th. Analysts expect OmniAb to post earnings of ($0.13) per share and revenue of $10.13 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
OmniAb Price Performance
OABI opened at $3.31 on Monday. The business’s 50-day moving average price is $3.43 and its two-hundred day moving average price is $3.81. OmniAb has a 1 year low of $3.05 and a 1 year high of $5.72. The company has a market capitalization of $467.42 million, a price-to-earnings ratio of -5.34 and a beta of -0.14.
Insider Buying and Selling at OmniAb
In other OmniAb news, insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now owns 343,190 shares of the company’s stock, valued at $1,111,935.60. This trade represents a 6.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Matthew W. Foehr sold 41,811 shares of OmniAb stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $135,467.64. Following the completion of the sale, the chief executive officer now directly owns 3,749,639 shares in the company, valued at $12,148,830.36. This represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock valued at $376,601 in the last 90 days. 8.60% of the stock is currently owned by company insiders.
OmniAb Company Profile
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Featured Articles
- Five stocks we like better than OmniAb
- Buy P&G Now, Before It Sets A New All-Time High
- How to Build the Ultimate Everything ETF Portfolio
- How to Choose Top Rated Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
